Biblio

Export 55 results:
Author Title Type Year
Filters: Author is Pasquier, Florence  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Health Knowledge, Attitudes, Practice
R. Le Bouc, Marelli, C., Beaufils, E., Berr, C., Hommet, C., Touchon, J., Pasquier, F., and Deramecourt, V., “Limiting Factors of Brain Donation in Neurodegenerative Diseases: The Example of French Memory Clinics.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1075-83, 2016.
Humans
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
R. Le Bouc, Marelli, C., Beaufils, E., Berr, C., Hommet, C., Touchon, J., Pasquier, F., and Deramecourt, V., “Limiting Factors of Brain Donation in Neurodegenerative Diseases: The Example of French Memory Clinics.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1075-83, 2016.
L. Grangeon, Paquet, C., Bombois, S., Quillard-Muraine, M., Martinaud, O., Bourre, B., Lefaucheur, R., Nicolas, G., Dumurgier, J., Gerardin, E., Jan, M., Laplanche, J. - L., Peoc'h, K., Hugon, J., Pasquier, F., Maltête, D., Hannequin, D., and Wallon, D., “Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein.”, J Alzheimers Dis, vol. 51, no. 3, pp. 905-13, 2016.
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
Interferon-gamma
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
International Cooperation
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
Lewy Body Disease
L. Grangeon, Paquet, C., Bombois, S., Quillard-Muraine, M., Martinaud, O., Bourre, B., Lefaucheur, R., Nicolas, G., Dumurgier, J., Gerardin, E., Jan, M., Laplanche, J. - L., Peoc'h, K., Hugon, J., Pasquier, F., Maltête, D., Hannequin, D., and Wallon, D., “Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein.”, J Alzheimers Dis, vol. 51, no. 3, pp. 905-13, 2016.
Magnetic Resonance Imaging
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
Male
L. Grangeon, Paquet, C., Bombois, S., Quillard-Muraine, M., Martinaud, O., Bourre, B., Lefaucheur, R., Nicolas, G., Dumurgier, J., Gerardin, E., Jan, M., Laplanche, J. - L., Peoc'h, K., Hugon, J., Pasquier, F., Maltête, D., Hannequin, D., and Wallon, D., “Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein.”, J Alzheimers Dis, vol. 51, no. 3, pp. 905-13, 2016.
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
Mental Status Schedule
L. Grangeon, Paquet, C., Bombois, S., Quillard-Muraine, M., Martinaud, O., Bourre, B., Lefaucheur, R., Nicolas, G., Dumurgier, J., Gerardin, E., Jan, M., Laplanche, J. - L., Peoc'h, K., Hugon, J., Pasquier, F., Maltête, D., Hannequin, D., and Wallon, D., “Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein.”, J Alzheimers Dis, vol. 51, no. 3, pp. 905-13, 2016.
Middle Aged
L. Grangeon, Paquet, C., Bombois, S., Quillard-Muraine, M., Martinaud, O., Bourre, B., Lefaucheur, R., Nicolas, G., Dumurgier, J., Gerardin, E., Jan, M., Laplanche, J. - L., Peoc'h, K., Hugon, J., Pasquier, F., Maltête, D., Hannequin, D., and Wallon, D., “Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein.”, J Alzheimers Dis, vol. 51, no. 3, pp. 905-13, 2016.
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
Neurodegenerative Diseases
R. Le Bouc, Marelli, C., Beaufils, E., Berr, C., Hommet, C., Touchon, J., Pasquier, F., and Deramecourt, V., “Limiting Factors of Brain Donation in Neurodegenerative Diseases: The Example of French Memory Clinics.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1075-83, 2016.
Neuropsychological Tests
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
Peptide Fragments
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
Phenotype
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
Phosphorylation
L. Grangeon, Paquet, C., Bombois, S., Quillard-Muraine, M., Martinaud, O., Bourre, B., Lefaucheur, R., Nicolas, G., Dumurgier, J., Gerardin, E., Jan, M., Laplanche, J. - L., Peoc'h, K., Hugon, J., Pasquier, F., Maltête, D., Hannequin, D., and Wallon, D., “Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein.”, J Alzheimers Dis, vol. 51, no. 3, pp. 905-13, 2016.
Physicians
R. Le Bouc, Marelli, C., Beaufils, E., Berr, C., Hommet, C., Touchon, J., Pasquier, F., and Deramecourt, V., “Limiting Factors of Brain Donation in Neurodegenerative Diseases: The Example of French Memory Clinics.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1075-83, 2016.
Practice Guidelines as Topic
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
Recombinant Fusion Proteins
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.
Retrospective Studies
R. Le Bouc, Marelli, C., Beaufils, E., Berr, C., Hommet, C., Touchon, J., Pasquier, F., and Deramecourt, V., “Limiting Factors of Brain Donation in Neurodegenerative Diseases: The Example of French Memory Clinics.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1075-83, 2016.
L. Grangeon, Paquet, C., Bombois, S., Quillard-Muraine, M., Martinaud, O., Bourre, B., Lefaucheur, R., Nicolas, G., Dumurgier, J., Gerardin, E., Jan, M., Laplanche, J. - L., Peoc'h, K., Hugon, J., Pasquier, F., Maltête, D., Hannequin, D., and Wallon, D., “Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein.”, J Alzheimers Dis, vol. 51, no. 3, pp. 905-13, 2016.
Saponins
F. Pasquier, Sadowsky, C., Holstein, A., Leterme, G. Le Prince, Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., and J Ryan, M., “Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1131-43, 2016.

Pages